
PIROUETTE #ACC21



Trial Description: Patients with HFpEF were randomized to pirfenidone vs. placebo.



RESULTS

 Change in myocardial extracellular volume (%) from baseline to 52 weeks: -0.7 in the pirfenidone group vs. 0.5 in the placebo group (p = 0.009)

CONCLUSIONS

- Among patients with HFpEF, pirfenidone appeared to be beneficial
- Pirfenidone was associated with a modest reduction in myocardial fibrosis, as assessed by cardiac MRI, compared with placebo
- The clinical significance of this finding is unknown

Presented by Dr. Christopher Miller at ACC.21